R. STUPP, M.E. HEGI, W.P. MASON, M.J. VAN DEN BENT, M.J. TAPHOORN, R.C. JANZER, S.K. LUDWIN, A. ALLGEIER, B. FISHER, K. BELANGER, P. HAU, A.A. BRANDES, J. GIJTENBEEK, C. MAROSI, C.J. VECHT, K. MOKHTARI, P. WESSELING, S. VILLA, E. EISENHAUER, T. GORLIA, M. WELLER, D. LACOMBE, J.G. CAIRNCROSS, R.O. MIRIMANOFF; European Organization for Reserach and Treatment of Cancer (EORTC) Brain Tumour and Radiation Oncology Groups: National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temzolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC/NCIC trial. Lancet Oncol 10(5): 459-66, 2009.
M. MAUER, R. STUPP, M.J.B. TAPHOORN, C. COENS, D. OSOBA,
C. MAROSI, R. WONG, W. DE WITTE, J.G. CAIRNCROSS, F. EFFICACE,
R.O. MIRIMANOFF, P. FORSYTH, M.J. VAN DEN BENT, M. WELLER,
A. BOTTOMLEY. The prognostic value of health-related quality-of-life
data in predicting survival in glioblastoma cancer patients:
results from an international randomised phase III EORTC Brain
Tumour and Radiation Oncology Groups, and NCIC Clinical Trials
Group study. Br J. Cancer 97(3): 302-7, 2007.
R. STUPP, M.E. HEGI, M.J. VAN DEN BENT, M. WELLER, R.O MIRIMANOFF,
J.G. CAIRNCROSS; European Organisation for Research and Treatment
of cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group. Changing paradigms
? an update on the multidisciplinary management of malignant
glioma. Oncologist 11: 165-180, 2006.
M.J. VAN DEN BENT, A. CARPENTIER, A.A. BRANDES, M. SANSON, M.J.B. TAPHOORN, H.J.J.A. BERNSEN, M. FRENAY, C.C. TIJSSEN, W. GRISOLD, L. SIPOS, H. HAAXMA-REICHE, J.M. KROS, M. VAN KOUWENHOVEN, CH. J. VECHT, A. ALLGEIER, D. LACOMBE, T GORLIA. Adjuvant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24(18): 2715-22, 2006.
M. PREUSSER, H. HEINZL, E. GELPI, K. SCHONEGGER, C. HABERLER, P. BIRNER, C. MAROSI, M. HEGI, T. GORLIA, J.A. HAINFELLNER. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: poor observer agreement limits clinical utility as prognostic factors. Cancer 107(1): 162-70, 2006.
R.O. MIRIMANOFF, T. GORLIA, W. MASON, M.J. VAN DEN BENT, R.D. KORTMANN, B. FISHER, M. RENI, A.A. BRANDES, J. CURSCHMANN, S. VILLA, G. CAIRNCROSS, A. ALLGEIER, D. LACOMBE, R. STUPP. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 2698122981 – NCIC CE3 phase III randomized trial. J Clin Oncol 24(16): 2563-9, 2006.
M.E. HEGI , A.C. DISERENS, T. GORLIA, M.F. HAMOU, N. DE TRIBOLET, M. WELLER, J.M. KROS, J.A. HAINFELLNER, W. MASON, L. MARIANI, J. BROMBERG, P. HAU, R. MIRIMANOFF, J.G. CAIRNCROSS, R.C. JANZER, R. STUPP. MGMT Gene silencing and benefit from Temozolomide in glioblastoma. N Engl J Med 352 (10): 997-1003, 2005.
R. STUPP, W. MASON, M. VAN DEN BENT, M. WELLER, B. FISHER, M. TAPHOORN, K. BELANGER, A. BRANDES, C. MAROSI, U. BOGDAHN, J. CURSCHMANN, R. JANZER, S. LUDWIN, T. GORLIA, A. ALLGEIER, D. LACOMBE, J. CAIRNCROSS, E. EISENHAUER, R. MIRIMANOFF, for the EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER BRAIN TUMOR and RADIOTHERAPY and the NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10): 987-996, 2005.
M.J. VAN DEN BENT, D. AFRA, O. DE WITTE, M. BEN HASSEL, S. SCHRAUB, K. HOANG-XUAN, P.O. MALMSTRÖM, L. COLLETTE, M. PIERART, R. MIRIMANOFF, A.B.M.F. KARIM, for the EORTC RADIOTHERAPY and BRAIN TUMOR GROUPS and the UK MEDICAL RESEARCH COUNCIL. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 366: 985-990, 2005.
M.J. VAN DEN BENT, M.J. TAPHOORN, A.A. BRANDES, J. MENTEN, R. STUPP, M. FRENAY, O-L. CHINOT, J.M. KROS, C.C.D VAN DER RIJT, C.J. VECHT, A. ALLGEIER, T. GORLIA. Phase II study of first line chemotherapy with temozolomide in recurrent oligodendroglial tumors; the European Organization for Research and Treatment of Cancer Brain Tumour Group study 26971. J Clin Oncol 21: 2525-2528, 2003.
M.J. VAN DEN BENT, O. CHINOT, W. BOOGERD, J.M. BRAVO-MARQUES, M.J. TAPHOORN, J.M. KROS, C.D.D. VAN DE RIJT, C.J. VECHT, N. DE BEULE, B. BARON. EORTC Brain Tumor Group study 26972: Second line chemotherapy with Temozolomide in recurrent oligodendroglioma after PCV-chemotherapy. A Phase II study. Ann Oncol 14: 599-602, 2003.
K. HOANG XUAN, L. TAILLANDIER, O. CHINOT, P. SOUBEYRAN, U. BOGDHAN, J. HILDEBRAND, M. FRENAY, N. DE BEULE, J.Y. DELATTRE and B. BARON. Chemotherapy alone as Initial Treatment for Primary CNS Lymphoma in Patients older than 60 years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21 (14): 2726 - 2731, 2003.
M.J. VAN DEN BENT, W. GRISOLD, D. FRAPPAZ, R. STUPP, J.P. DESIR, T. LESIMPLE, C. DITTRICH, M.J.A. DE JONGE, A. BRANDES, M. FRENAY, A.F. CARPENTIER, P. CHOLLET, J. OLIVEIRA, B.BARON, D. LACOMBE, M. SCHUESSLER, P. FUMOLEAU on behalf of the EORTC NEW DRUG DEVELOPMENT GROUP AND BRAIN TUMOR GROUP. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14: 1732-1734, 2003.
C. TWELVES, M. CAMPONE, B. COUDERT, M. VAN DEN BENT, M. DE JONGE, C. DITTRICH, R. RAMPLING, R. SORIO, D. LACOMBE, C. DE BALINCOURT, P. FUMOLEAU. Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol 13: 777-780, 2002.
E. RAYMOND, M. CAMPONE, R. STUPP, J. MENTEN, P. CHOLLET, T. LESIMPLE, R. FETY-DEPORTE, D. LACOMBE, X. PAOLETTI, P. FUMOLEAU. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 38 (10): 1348-1350, 2002.
F. PIGNATTI, M. VAN DEN BENT, D. CURRAN, C. DEBRUYNE, R. SYLVESTER, P. THERASSE, D. AFRA, P. CORNU, M. BOLLA, C. VECHT, A.B. KARIM for the EORTC BRAIN TUMOR COOPERATIVE GROUP and RADIOTHERAPY GROUP. Prognostic factors for survival in adult patients with cerebral low-grade gliomas. J Clin Oncol 20 (8): 2076-2084, 2002.
A.B.M.F. KARIM, D. AFRA, P. CORNU, N. BLEEHAN, S. SCHRAUB, O. DE WITTE, F. DARCEL, S. STENNING, M. PIERART, and M. VAN GLABBEKE. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organisation for research council study 22845 with the Medical Research Council (MRC) study BR04: An interim analysis. Int J Radiat Oncol Biol Phys 52 (2): 316-324, 2002.
A.B.M.F. KARIM, B. MAAT, R. HATLEVOLL, J. MENTEN, E.H.J. RUTTEN, D.G.T. THOMAS, F. MASCARENHAS, J.C. HORIOT, L.M. PARVINEN, M. van REIJN, J.J. JAGER, M.G. FABRINI, A.M. van ALPHEN, H.P. HAMERS, L. GASPAR, E. NOORDMAN, M. PIERART, and M. van GLABBEKE. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36: 549-556, 1996.
J. HILDEBRAND, T. SAHMOUD, F. MIGNOLET, J.M. BRUCHER, D. AFRA, AND THE EORTC BRAIN TUMOR GROUP. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44:1479-1483, 1994.
EORTC BRAIN TUMOR GROUP. Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 27: 568-571, 1991.
EORTC BRAIN TUMOUR COOPERATIVE GROUP. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6-dioxodiethylester) in recurring supratentorial malignant brain gliomas - A phase II study. Eur J Cancer Clin Oncol 21: 143-146, 1985.
